Ace Therapeutics is a global leading provider of IBD research services. Our services include the advancement of basic IBD research, experimental modeling and preclinical drug studies, providing researchers with a integrated platform to develop new therapies.
With a wealth of experience in taking novel therapeutic agents from early-stage in vitro testing to candidate nomination, Ace Therapeutics' technical team is well-equipped to assist and advise on appropriate models and custom protocols in accordance with study objectives.
We accelerate decision-making milestones in IBD drug development, supporting our clients to delve deeper into disease mechanisms and translate these discoveries into novel solutions.
We apply decades of early-stage drug development experience and a fully customized approach to hone in on the specialized therapy for IBD.
Equipped to perform flexible colonoscopy assessments and magnetic resonance imaging (MRI) when required.
Our team of experts has developed a broad understanding of the inflammatory and immune mechanisms and pathways that underpin IBD pathology.
IBD drug discovery services can be offered as part of an integrated preclinical project package or as a stand-alone analytical option. Flexible approach with easy access to our global network of specialized laboratories.
Our team of skilled medicinal chemists and DMPK specialists offers a comprehensive drug discovery platform for IBD. We employ a diverse array of assays to examine crucial functions of inflammatory and immune cells, as well as microbes, enabling us to help clients develop groundbreaking therapies.